A citation-based method for searching scientific literature

Janice S Kwon, Angelica M Gutierrez-Barrera, Diana Young, Charlotte C Sun, Molly S Daniels, Karen H Lu, Banu Arun. J Clin Oncol 2010
Times Cited: 99







List of co-cited articles
743 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Clinical and pathologic characteristics of patients with BRCA-positive and BRCA-negative breast cancer.
Deann P Atchley, Constance T Albarracin, Adriana Lopez, Vicente Valero, Christopher I Amos, Ana Maria Gonzalez-Angulo, Gabriel N Hortobagyi, Banu K Arun. J Clin Oncol 2008
343
26

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
S R Young, Robert T Pilarski, Talia Donenberg, Charles Shapiro, Lyn S Hammond, Judith Miller, Karen A Brooks, Stephanie Cohen, Beverly Tenenholz, Damini Desai,[...]. BMC Cancer 2009
167
25

Incidence and outcome of BRCA mutations in unselected patients with triple receptor-negative breast cancer.
Ana M Gonzalez-Angulo, Kirsten M Timms, Shuying Liu, Huiqin Chen, Jennifer K Litton, Jennifer Potter, Jerry S Lanchbury, Katherine Stemke-Hale, Bryan T Hennessy, Banu K Arun,[...]. Clin Cancer Res 2011
341
24

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial.
Andrew Tutt, Mark Robson, Judy E Garber, Susan M Domchek, M William Audeh, Jeffrey N Weitzel, Michael Friedlander, Banu Arun, Niklas Loman, Rita K Schmutzler,[...]. Lancet 2010
20

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.
Peter C Fong, David S Boss, Timothy A Yap, Andrew Tutt, Peijun Wu, Marja Mergui-Roelvink, Peter Mortimer, Helen Swaisland, Alan Lau, Mark J O'Connor,[...]. N Engl J Med 2009
19

Meta-analysis of BRCA1 and BRCA2 penetrance.
Sining Chen, Giovanni Parmigiani. J Clin Oncol 2007
19

Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies.
A Antoniou, P D P Pharoah, S Narod, H A Risch, J E Eyfjord, J L Hopper, N Loman, H Olsson, O Johannsson, A Borg,[...]. Am J Hum Genet 2003
19

Germline BRCA1 mutations and a basal epithelial phenotype in breast cancer.
William D Foulkes, Ingunn M Stefansson, Pierre O Chappuis, Louis R Bégin, John R Goffin, Nora Wong, Michel Trudel, Lars A Akslen. J Natl Cancer Inst 2003
693
17

Prevalence of BRCA mutations in an unselected population of triple-negative breast cancer.
Anne-Renee Hartman, Rajesh R Kaldate, Lisa M Sailer, Lisa Painter, Charles E Grier, Robbin R Endsley, Marlena Griffin, Stephanie A Hamilton, Cynthia A Frye, Mark A Silberman,[...]. Cancer 2012
120
17

Pathologic complete response rates in young women with BRCA1-positive breast cancers after neoadjuvant chemotherapy.
Tomasz Byrski, Jacek Gronwald, Tomasz Huzarski, Ewa Grzybowska, Magdalena Budryk, Malgorzata Stawicka, Tomasz Mierzwa, Marek Szwiec, Rafal Wisniowski, Monika Siolek,[...]. J Clin Oncol 2010
367
16

Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality.
Susan M Domchek, Tara M Friebel, Christian F Singer, D Gareth Evans, Henry T Lynch, Claudine Isaacs, Judy E Garber, Susan L Neuhausen, Ellen Matloff, Rosalind Eeles,[...]. JAMA 2010
824
15

Triple-negative breast cancer: clinical features and patterns of recurrence.
Rebecca Dent, Maureen Trudeau, Kathleen I Pritchard, Wedad M Hanna, Harriet K Kahn, Carol A Sawka, Lavina A Lickley, Ellen Rawlinson, Ping Sun, Steven A Narod. Clin Cancer Res 2007
15

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
L Robertson, H Hanson, S Seal, M Warren-Perry, D Hughes, I Howell, C Turnbull, R Houlston, S Shanley, S Butler,[...]. Br J Cancer 2012
66
19

BRCA in breast cancer: ESMO Clinical Practice Guidelines.
J Balmaña, O Díez, I T Rubio, F Cardoso. Ann Oncol 2011
114
12

Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study.
Lisa A Carey, Charles M Perou, Chad A Livasy, Lynn G Dressler, David Cowan, Kathleen Conway, Gamze Karaca, Melissa A Troester, Chiu Kit Tse, Sharon Edmiston,[...]. JAMA 2006
11


Efficacy of neoadjuvant Cisplatin in triple-negative breast cancer.
Daniel P Silver, Andrea L Richardson, Aron C Eklund, Zhigang C Wang, Zoltan Szallasi, Qiyuan Li, Nicolai Juul, Chee-Onn Leong, Diana Calogrias, Ayodele Buraimoh,[...]. J Clin Oncol 2010
639
11

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
E Comen, M Davids, T Kirchhoff, C Hudis, K Offit, M Robson. Breast Cancer Res Treat 2011
65
16

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
11

American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility.
Mark E Robson, Courtney D Storm, Jeffrey Weitzel, Dana S Wollins, Kenneth Offit. J Clin Oncol 2010
295
10

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
625
10

Preventing future cancers by testing women with ovarian cancer for BRCA mutations.
Janice S Kwon, Molly S Daniels, Charlotte C Sun, Karen H Lu. J Clin Oncol 2010
48
20

Prevalence of BRCA1 and BRCA2 mutations in triple negative breast cancer.
D G Evans, A Howell, D Ward, F Lalloo, J L Jones, D M Eccles. J Med Genet 2011
50
20

Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, Joel Parker, Trevor Hastie, J S Marron, Andrew Nobel, Shibing Deng, Hilde Johnsen, Robert Pesich, Stephanie Geisler,[...]. Proc Natl Acad Sci U S A 2003
9

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy.
Hannah Farmer, Nuala McCabe, Christopher J Lord, Andrew N J Tutt, Damian A Johnson, Tobias B Richardson, Manuela Santarosa, Krystyna J Dillon, Ian Hickson, Charlotte Knights,[...]. Nature 2005
9

Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
Mary-Claire King, Joan H Marks, Jessica B Mandell. Science 2003
9

Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. The Breast Cancer Linkage Consortium.
D Ford, D F Easton, M Stratton, S Narod, D Goldgar, P Devilee, D T Bishop, B Weber, G Lenoir, J Chang-Claude,[...]. Am J Hum Genet 1998
9

Cost-effectiveness of testing for breast cancer susceptibility genes.
Margaret L Holland, Alissa Huston, Katia Noyes. Value Health 2009
31
29

Prevalence of BRCA mutations among women with triple-negative breast cancer (TNBC) in a genetic counseling cohort.
Rachel Greenup, Adam Buchanan, Wendy Lorizio, Keelia Rhoads, Salina Chan, Tracey Leedom, Robin King, Jane McLennan, Beth Crawford, P Kelly Marcom,[...]. Ann Surg Oncol 2013
120
9

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
355
9

Limited family structure and BRCA gene mutation status in single cases of breast cancer.
Jeffrey N Weitzel, Veronica I Lagos, Carey A Cullinane, Patricia J Gambol, Julie O Culver, Kathleen R Blazer, Melanie R Palomares, Katrina J Lowstuter, Deborah J MacDonald. JAMA 2007
130
8

American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer.
M Elizabeth H Hammond, Daniel F Hayes, Mitch Dowsett, D Craig Allred, Karen L Hagerty, Sunil Badve, Patrick L Fitzgibbons, Glenn Francis, Neil S Goldstein, Malcolm Hayes,[...]. J Clin Oncol 2010
8

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications.
T Sørlie, C M Perou, R Tibshirani, T Aas, S Geisler, H Johnsen, T Hastie, M B Eisen, M van de Rijn, S S Jeffrey,[...]. Proc Natl Acad Sci U S A 2001
8

Pathological features and BRCA1 mutation screening in premenopausal breast cancer patients.
J Chang, S G Hilsenbeck, J H Sng, J Wong, G C Ragu. Clin Cancer Res 2001
27
29

Major improvement in the efficacy of BRCA1 mutation screening using morphoclinical features of breast cancer.
R Lidereau, F Eisinger, M H Champème, C Noguès, I Bièche, D Birnbaum, C Pallud, J Jacquemier, H Sobol. Cancer Res 2000
59
13

The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews.
J P Struewing, P Hartge, S Wacholder, S M Baker, M Berlin, M McAdams, M M Timmerman, L C Brody, M A Tucker. N Engl J Med 1997
8

Variation of breast cancer risk among BRCA1/2 carriers.
Colin B Begg, Robert W Haile, Ake Borg, Kathleen E Malone, Patrick Concannon, Duncan C Thomas, Bryan Langholz, Leslie Bernstein, Jørgen H Olsen, Charles F Lynch,[...]. JAMA 2008
202
8

Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study.
Noah D Kauff, Susan M Domchek, Tara M Friebel, Mark E Robson, Johanna Lee, Judy E Garber, Claudine Isaacs, D Gareth Evans, Henry Lynch, Rosalind A Eeles,[...]. J Clin Oncol 2008
348
8

Predicting the likelihood of carrying a BRCA1 or BRCA2 mutation: validation of BOADICEA, BRCAPRO, IBIS, Myriad and the Manchester scoring system using data from UK genetics clinics.
A C Antoniou, R Hardy, L Walker, D G Evans, A Shenton, R Eeles, S Shanley, G Pichert, L Izatt, S Rose,[...]. J Med Genet 2008
123
8

A new scoring system for the chances of identifying a BRCA1/2 mutation outperforms existing models including BRCAPRO.
D G R Evans, D M Eccles, N Rahman, K Young, M Bulman, E Amir, A Shenton, A Howell, F Lalloo. J Med Genet 2004
178
8

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, Jocelyne Jacquemier, Thomas J Anderson, Peter P Osin, Lesley McGuffog, Douglas F Easton. J Clin Oncol 2002
580
8

Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer.
Cornelia Liedtke, Chafika Mazouni, Kenneth R Hess, Fabrice André, Attila Tordai, Jaime A Mejia, W Fraser Symmans, Ana M Gonzalez-Angulo, Bryan Hennessy, Marjorie Green,[...]. J Clin Oncol 2008
8

Prediction of BRCA1 status in patients with breast cancer using estrogen receptor and basal phenotype.
Sunil R Lakhani, Jorge S Reis-Filho, Laura Fulford, Frederique Penault-Llorca, Marc van der Vijver, Suzanne Parry, Timothy Bishop, Javier Benitez, Carmen Rivas, Yves-Jean Bignon,[...]. Clin Cancer Res 2005
444
8

Molecular portraits of human breast tumours.
C M Perou, T Sørlie, M B Eisen, M van de Rijn, S S Jeffrey, C A Rees, J R Pollack, D T Ross, H Johnsen, L A Akslen,[...]. Nature 2000
8

BRCAPRO validation, sensitivity of genetic testing of BRCA1/BRCA2, and prevalence of other breast cancer susceptibility genes.
Donald A Berry, Edwin S Iversen, Daniel F Gudbjartsson, Elaine H Hiller, Judy E Garber, Beth N Peshkin, Caryn Lerman, Patrice Watson, Henry T Lynch, Susan G Hilsenbeck,[...]. J Clin Oncol 2002
325
8


Basal cytokeratin and epidermal growth factor receptor expression are not predictive of BRCA1 mutation status in women with triple-negative breast cancers.
Laura C Collins, Anthony Martyniak, Michaela J Kandel, Zsofia K Stadler, Serena Masciari, Alexander Miron, Andrea L Richardson, Stuart J Schnitt, Judy E Garber. Am J Surg Pathol 2009
50
16

Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations.
Soley Bayraktar, Angelica M Gutierrez-Barrera, Diane Liu, Tunc Tasbas, Ugur Akar, Jennifer K Litton, E Lin, Constance T Albarracin, Funda Meric-Bernstam, Ana M Gonzalez-Angulo,[...]. Breast Cancer Res Treat 2011
64
12

Germline BRCA mutation evaluation in a prospective triple-negative breast cancer registry: implications for hereditary breast and/or ovarian cancer syndrome testing.
Priyanka Sharma, Jennifer R Klemp, Bruce F Kimler, Jonathan D Mahnken, Larry J Geier, Qamar J Khan, Manana Elia, Carol S Connor, Marilee K McGinness, Joshua M W Mammen,[...]. Breast Cancer Res Treat 2014
91
8

Estrogen receptor status in BRCA1- and BRCA2-related breast cancer: the influence of age, grade, and histological type.
William D Foulkes, Kelly Metcalfe, Ping Sun, Wedad M Hanna, Henry T Lynch, Parviz Ghadirian, Nadine Tung, Olufunmilayo I Olopade, Barbara L Weber, Jane McLennan,[...]. Clin Cancer Res 2004
215
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.